Why the study?
Little is known about the sex-specific impact of drug optimization tools like the FORTA list on drug use and clinical endpoints in older people.
Does FORTA list-based medication optimization improve medication quality and clinical endpoints equally in older hospitalized men and women?
Does FORTA list-based medication optimization improve medication quality and clinical endpoints equally in older hospitalized men and women?
The FORTA list-based medication optimization improves medication quality and functional outcomes equally in older men and women, while reducing adverse drug events more prominently in women.
Answers are grounded in this paper and cite their sources.
Supports uniform FORTA use in both sexes now; extends VALFORTA as the first sex-stratified RCT of a listing tool.
BACKGROUND: Little is known about the sex-specific impact of drug optimization tools such as the Fit fOR The Aged (FORTA) list on drug use and relevant clinical endpoints in older people. OBJECTIVE: We aimed to detect gender differences of interventional effects on medication quality and related clinical effects in the VALFORTA trial. PATIENTS AND METHODS: A sex-specific analysis of data from 409 patients (147 men and 262 women, mean age 79.4 and 82.7 years, respectively) in acute geriatric care comparing the control and FORTA intervention groups was performed. Changes of the FORTA score (sum of over- and undertreatment errors per patient), the incidence of adverse drug events (ADEs) during hospitalization, and several clinically relevant endpoints [e.g., the Barthel index (BI)] were tested for equivalence at a 20% margin. "Success" or "failure" for the development of these clinical endpoints was defined and their frequencies compared by a risk reduction analysis. RESULTS: Sex differences were insignificant for the reduction of the FORTA score, the improvement of BI, or over- and undertreatment errors (p > 0.05). In women only, the FORTA intervention significantly increased the number of patients without an ADE (p = 0.010). Statistical sex equivalence was found for the improvement of the FORTA scores, BI, and the number of prevented events (e.g., falls, confusion, or renal failure) (p < 0.05), but not for the improvement of specific mistreatments or over- and undertreatment scores under altered inclusion criteria (p > 0.05). CONCLUSIONS: Both sexes benefit equally from the FORTA intervention regarding the amelioration of the quality of drug treatment as well as several clinically relevant outcomes. In addition, the positive impact of the FORTA intervention on the number of adverse drug events appears to be greater in women. TRIAL REGISTRATION NUMBER: DRKS00000531.
No takes yet. Share an insight, caveat, or question.
Schmitt et al. (2022) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: